August 30, 2018
An independent body that offers guidance to improve health and social care in England recommended against the use of axicabtagene ciloleucel, one of two chimeric antigen receptor T-cell therapies already approved in the United States and European Union. The National Institute for Health and Care Excellence (NICE) issued draft guidance today that said axicabtagene ciloleucel...
Continue Reading
There may be a way to detect multiple myeloma (MM) earlier — effectively shortening the longer diagnostic interval that is typically associated with the diagnosis of MM — using basic information derived from routine blood panels already used in the primary care setting, according to a study published in British Journal of General Practice.1 The National Institute for...
Continue Reading
The deep and durable phase I responses seen with the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with relapsed/refractory heavily pretreated multiple myeloma have prompted a phase II study, which is currently ongoing, according to Noopur Raje, MD. Data from the phase I CRB-401 trial showed bb2121 was associated with a 95.5% overall response...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand